Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Endoscopic surveillance influences mortality from Barrett's associated esophageal cancers

This month's issue of Gastroenterology evaluates the impact of endoscopic surveillance on mortality from Barrett's esophagus–Aasociated esophageal adenocarcinomas.

News image

Although patients with Barrett’s esophagus commonly undergo endoscopic surveillance, its effectiveness in reducing mortality from esophageal/gastroesophageal junction adenocarcinomas has not been evaluated rigorously.

Dr Douglas Corley and colleagues from California, USA  performed a case-control study in a community-based setting.

Among 8272 members with Barrett’s esophagus, the researchers identified 351 esophageal adenocarcinoma.

Of these, 70 were found in persons who had a prior diagnosis of Barrett’s esophagus, and 51 of these patients died, with 38 as a result of the cancers.

Surveillance histories were contrasted with a sample of 101 living persons with Barrett’s esophagus, matched for age, sex, and duration of follow-up evaluation.

Surveillance within 3 years was not associated with a decreased risk of death from esophageal adenocarcinoma.

Surveillance within 3 years was not associated with a decreased risk of death
Gastroenterology

Fatal cases were nearly as likely to have received surveillance as were controls.

A Barrett’s esophagus length longer than 3 cm, and prior dysplasia each were associated with subsequent mortality, but adjustment for these did not change the main findings.

Although all patients should be included in evaluations of effectiveness, excluding deaths related to cancer treatment and patients who failed to complete treatment, changed the magnitude, but not the significance, of the association.

Dr Corley's team concludes, "Endoscopic surveillance of patients with Barrett’s esophagus was not associated with a substantially decreased risk of death from esophageal adenocarcinoma."

"The results do not exclude a small to moderate benefit."

"However, if such a benefit exists, our findings indicate that it is substantially smaller than currently estimated."

"The effectiveness of surveillance was influenced partially by the acceptability of existing treatments and the occurrence of treatment-associated mortality."

Gastroenterol 2013: 145(2): 312-319
01 August 2013

Go to top of page Email this page Email this page to a colleague

 26 May 2015

Advanced search
 26 May 2015 
Calcium channel blockers and GI bleeds
 26 May 2015 

Risk factors for celiac disease

 26 May 2015 
Antimicrobials for intraabdominal infection
 25 May 2015 
Risk of GI bleeds with NSAIDs
 25 May 2015 
Colorectal cancer screening
 25 May 2015 
Saccharomyces boulardii and H. pylori
 22 May 2015 
Treatment with anti-integrin antibodies in IBD
 22 May 2015 
Care of patients with GERD
 22 May 2015 
Colonoscopy screening for colorectal cancer
 21 May 2015 
Imaging for hepatocellular carcinoma
 21 May 2015 
Lymphoma in IBD
 21 May 2015 
Serrated polyps and colorectal cancer
 20 May 2015 
Refractory metastatic colorectal cancer
 20 May 2015 
Surveillance in long-segment Barrett's
 20 May 2015 
Pancreatic neuroendocrine tumors
 19 May 2015 
PPIs and cryptogenic liver abscess
 19 May 2015 
Anti-integrin antibodies in IBD
 19 May 2015 
Metabolic syndrome and Barrett's
 18 May 2015 
HLA haplotypes and primary sclerosing cholangitis
 18 May 2015 
Safety of PPI
 18 May 2015 
ESPGHAN celiac guidelines
 15 May 2015 
Management of nonhospitalized ulcerative colitis
 15 May 2015 
Diabetes and infections in IBD with immunomodulation
 15 May 2015 
Microscopic colitis risk with PPIs/NSAIDs
 14 May 2015 
Diagnosis of spontaneous bacterial peritonitis
 14 May 2015 
Mortality in US patients with cirrhosis
 14 May 2015 
Radiation exposure during ERCP
 13 May 2015 
Predictors of IBD
 13 May 2015 
Psychological distress and liver disease mortality
 13 May 2015 
Hypnotherapy in IBS/IBD
 12 May 2015 
Bleeding in NSAID users with H.pylori
 12 May 2015 
Capsule colonoscopy detects colorectal polyps
 12 May 2015 
Anti-TNF biologics in acute severe ulcerative colitis
 11 May 2015 
Management of Barrett's esophagus
 11 May 2015 
Marker to detect recurrence of Crohn's
 11 May 2015 
Thalidomide for IBD
 08 May 2015 
Surveillance colonoscopy in colorectal cancer
 08 May 2015 
HCV treatment with compensated cirrhosis
 08 May 2015 
Medical management of Crohn's
 07 May 2015 
Surgical complications in ulcerative colitis
 07 May 2015 
Combination therapy for noncirrhostic patients
 07 May 2015 
Anxiety and new-onset dyspepsia
 06 May 2015 
PPIs and spontaneous bacterial peritonitis
 06 May 2015 
Infant feeding and celiac disease
 06 May 2015 
Preventing recurrent C. diff infection
 05 May 2015 
Fatigue in primary sclerosing cholangitis
 05 May 2015 
Annual CT scans after esophagectomy for cancer
 05 May 2015 
Prevalence of eosinophilic esophagitis
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Endoscope storage and microbial colonization
 04 May 2015 
Menarche and NAFLD
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Dietary supplement hepatotoxicity
 30 April 2015 
Risk factors for primary sclerosing cholangitis
 30 April 2015 
Neoadjuvant chemoradiotherapy for esophageal cancer
 30 April 2015 
Botulinum toxin A for the treatment of obesity
 29 April 2015 
Hepatocellular carcinoma surveillance in HBV
 29 April 2015 
Liver enzyme elevations after anti-TNF therapy in IBD

 29 April 2015 
Response to sorafenib in hepatocellular carcinoma

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us